Previous 10 | Next 10 |
Becton, Dickinson press release (NYSE:BDX): Q1 Non-GAAP EPS of $3.64 beats by $0.79. Revenue of $5B (-6.0% Y/Y) beats by $240M. The company raised its full year revenue and adjusted EPS guidance. The company now expects fiscal year 2022 revenues to be in the range of $19.55 billion to $...
BD REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS - Revenue of $5.0 billion declined 6.0% as reported and 5.9% on currency-neutral basis, due to a decline in worldwide COVID-only testing revenues to $185 million from $866 million in the prior year - Revenue driven by gr...
Becton, Dickinson (NYSE:BDX) is scheduled to announce Q1 earnings results on Thursday, February 3rd, before market open. The consensus EPS Estimate is $2.85 (-10.7% Y/Y) and the consensus Revenue Estimate is $4.76B (-3.1% Y/Y). Over the last 2 years, BDX has beaten EPS estimates 100% of the t...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Becton, Dickinson and Company's (NYSE:BDX) board approved the spinoff of its diabetes care business, which will be known as Embecta, and declared a pro rata distribution of Embecta shares of to BDX shareholders. The board voted unanimously to approve the spinoff to occur on Apr. 1, concl...
BD Board of Directors Approves embecta Spinoff and Declares Distribution of embecta Stock PR Newswire FRANKLIN LAKES, N.J. , Feb. 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today annou...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Cumulatively, the market has risen 100% in the last three...
Becton, Dickinson and Company (NYSE:BDX) announced the acquisition of Cytognos, a closely held life sciences company from Vitro S.A. Cytognos, based in Salamanca, Spain, offers flow cytometry solutions for blood cancer diagnosis, the detection of minimal residual disease (MRD) and immune moni...
BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A. Informatics Capabilities Help Expand BD Data Analytics Capabilities and Understanding of Cancer and Other Chronic Diseases PR Newswire FRANKLI...
The demand for medical equipment & supplies is rising exponentially with the emergence of severe illnesses such as the ongoing Coronavirus pandemic and the growing elderly population. So, Baxter International (BAX) and Becton Dickinson and Company (BDX) should benefit. But which of these ...
News, Short Squeeze, Breakout and More Instantly...
Becton Dickinson and Company Company Name:
BDX Stock Symbol:
NYSE Market:
Becton Dickinson and Company Website:
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases PR Newswire Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J. , July 25, 20...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials PR Newswire Company Committed to Support Global Health and Customers BD Taking all Available Measures to Mitigate Supplier Issue FRANKLIN LAKES, N.J. , July 10 , 2024...